CoChat

Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer

Soucy, Teresa A., Smith, Peter G., Rolfe, Mark · 2009 · Clinical Cancer Research

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

E3 ubiquitin ligases regulate many dynamic cellular processes important for cancer cell survival. Together with ubiquitin-activating enzyme (E1) and ubiquitin-conjugating enzymes (E2s), E3s catalyze the ubiquitination of numerous protein substrates that are subsequently targeted to the 26S proteasome for degradation. The clinical success of the proteasome inhibitor bortezomib has encouraged the evaluation of other components of the ubiquitin proteasome system for pharmaceutical intervention. Targeting specific E3s is particularly attractive because there is the potential to selectively block the degradation of certain cellular proteins and possibly avoid unwanted effects on other proteins. The cullin-RING ubiquitin E3 ligases (CRLs) represent the largest subfamily of E3s. The requirement that CRLs be activated by NEDD8 modification on the cullin protein offers an “achilles heel” for modulating this entire subfamily. NEDD8-activating enzyme (NAE) catalyzes the first step in the NEDD8 pathway and as such controls the activity of CRLs. In this article, we describe the role of the NEDD8 pathway in activating CRLs and discuss the preclinical findings with a first-in-class NAE inhibitor that is currently in phase I clinical trials for both solid tumor and hematological malignancies. In addition, we speculate where NAE inhibitors may find clinical utility.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-09-0343

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 53 references

Cited by

See all 244

Metadata

Authors
Soucy, T. A., Smith, P. G., & Rolfe, M.
Affiliations
Takeda Oncology (United States) (US)
Venue
Clinical Cancer Research
Published
2009-06-15
Volume
15
Issue
12
Pages
3912-3916
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2120380960
Cited by
222
References
53
Citations by year
2026: 6 · 2025: 10 · 2024: 11 · 2023: 12 · 2022: 13 · 2021: 12 · 2020: 13 · 2019: 19 · 2018: 11 · 2017: 11 · 2016: 12 · 2015: 13 · 2014: 16 · 2013: 17 · 2012: 16
FWCI
6.30
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
NEDD8-activating enzyme, cullin-RING ubiquitin ligases, E3 ubiquitin ligase, ubiquitin-proteasome system, protein degradation, cancer therapy, hematologic malignancies, solid tumors
MeSH terms
Bortezomib, NEDD8 Protein, Antineoplastic Agents, Boronic Acids, Cyclopentanes, Humans, Neoplasms, Pyrazines, Pyrimidines, Ubiquitins, Signal Transduction, NF-kappa B, Ubiquitin-Conjugating Enzymes, Ubiquitin-Activating Enzymes, Ubiquitin-Protein Ligases, Cullin Proteins, Proteasome Endopeptidase Complex, RING Finger Domains, Proteasome Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-0343
The paper
Soucy, T. A., Smith, P. G., & Rolfe, M. (2009). Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-0343

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.